Table 3.

Risk scoring system for ≥ grade 2 HFSR in patients receiving sorafenib

Predictive factor	Start sorafenib
Initial starting score	Initial score = 20
Impact of baseline factors
Female gender	Add 6
ECOG PS ≥1	Subtract 7
Lung metastases at baseline	Subtract 7
Liver metastases at baseline	Add 6
2 or more organs involved	Add 9
Baseline WBC >5.5	Add 5
Impact of HFSR risk by week of therapy
Week 1	Add 4
Week 2	Add 7
Week 3	Add 10
Week 4	Add 11
Week 5	Add 12
Week 6	Add 11
Week 7	Add 10
Week 8	Add 8
Total composite risk scorea	?

^aThe probability of developing HFSR during that given week while on sorafenib therapy can then be estimated from supplemental Figure S1 or supplemental Table S1 (available at Annals of Oncology online).

ECOG PS, Eastern Oncology Cooperative Oncology Group Performance Status; HFSR, hand-foot skin reaction; WBC, white blood cell.